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Introduction
Multiple myeloma (MM) is a hematologic malignancy originating from plasma cells, that typically produce a monoclonal immunoglobulin (M-protein). The type of heavy and light chain of this M-protein are specific to the myeloma clone, therefore it is used as a marker for diagnosis and monitoring of disease and response in MM.
In the course of MM, patients may develop monoclonal bands of different isotypes than the original myeloma M-protein [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Several terms have been used to describe this phenomenon, including abnormal protein band, oligoclonal protein bands, transient mono-or oligoclonal gammopathy, apparent isotype switch, oligoclonal humoral response, atypical serum immunofixation pattern, and in myeloma patients, as we will use in this study, secondary MGUS (sMGUS) 18 . We consider posttransplant MGUS as a subtype of sMGUS.
Secondary MGUS occurs more frequently after treatment with autologous stem cell transplantation (auto-SCT) (10-73%) 1-6;8-14;17 , than in patients who have not undergone auto-SCT (1.6-3.1%) 4;9 . Several studies also showed a higher frequency of sMGUS in patients treated with novel agents, when compared to conventional chemotherapy 7;16;17 . Importantly, sMGUS is not a sign of relapse or progression of MM 3;17;19;20 . In fact, some studies found that patients who develop sMGUS have a superior prognosis in terms of progression-free survival (PFS) and overall survival (OS) than those without sMGUS 1;2;4;6;9;10;12-14;17 . However, other studies, with often small sample size, concluded that the presence of sMGUS does not relate to the prognosis of MM, or that it is only associated with a better response but not with a benefit in PFS or OS 5;7;8;11 .
In MM allogeneic stem cell transplantation (allo-SCT) results in a high rate of molecular remissions and lower risk of relapse by virtue of the graft-versus-myeloma (GvM) effect 21;22 . However, because of high treatment-related mortality (TRM) especially after myeloablative conditioning and the emergence of the novel agents which are effective and have relatively mild toxicity, the value of this approach is disputed and remains to be determined in clinical trials.
After allo-SCT for various conditions, a high frequency of abnormal protein bands has been reported 1;5;19;20;23-25 . However, the total number of patients undergoing allo-SCT included in previous studies was very low, and allo-SCT was not always analyzed separately from other treatment regimens. Furthermore, most studies evaluated a heterogeneous population of patients with a variety of malignant and benign hematological disorders, and patients with MM were often not included.
Therefore, there are currently no data available regarding the frequency of sMGUS and its prognostic significance in MM patients who underwent allo-SCT. Here, we describe the occurrence of posttransplant MGUS and its association with response, PFS, and OS in this group of patients.
Methods

Patients, definitions, and diagnostic criteria
Between 1 January 2001 and 31 December 2012, 149 myeloma or primary plasma cell leukemia (pPCL), underwent a total of 154 allo-SCTs in the University Medical Center Utrecht (UMCU), Utrecht,
The Netherlands. Patients were treated according to clinical protocols, which were approved by the local ethics committee, and all patients gave their informed consent. When a patient received more than one allo-SCT in this period (n=4 patients), only successfully engrafted transplants were included in the analysis. Two patients experienced graft failure and two patients received two allo-SCTs several years apart during the inclusion period for this study. Cases were excluded from the analysis if insufficient data about protein bands were available (n=12 allo-SCTs in 11 patients). Altogether, 139 allo-SCTs in 138 patients were included in the analysis.
Diagnosis of MM or pPCL was based on standard clinical assessment. Secondary MGUS was defined as appearance of a protein band on immunofixation or electrophoresis that is different from the original myeloma M-protein in heavy-chain or light-chain isotype, or in its migration pattern. Mprotein analysis was performed using serum protein electrophoresis and immunofixation using the Sebia Hydragel system (Norcross, GA, USA), according to the manufacturer's instructions. M-proteins were detected by screening using amidoblack staining and a pentavalent antiserum directed against human IgG, IgA, IgM, kappa, and lambda, and typed using monovalent antisera. Serum M-protein levels were determined by densitometric scanning at 570 nm (HYRYS densitometer, Sebia), which has a lower limit of M-protein quantification of around 2.0 g/L.
Acute graft-versus-host-disease (GvHD) was grade I-IV according to Seattle criteria 26 
Results
Patient and transplant characteristics
We included a total of 138 patients who underwent 139 allo-SCTs. Hundred thirty-four patients (96.4%) were diagnosed with MM, while 5 patients (3.6%) had pPCL ( Table 1 .
Transplant outcome and survival
After allo-SCT, 56 patients (40.3%) achieved CR and at least VGPR was achieved in 104 patients (74.8%) ( Table 2) . Fifty-five patients (39.6%) developed acute GvHD of at least grade 2, and chronic GvHD occurred in 60 patients (43.2%). It was classified as extensive in 43 patients and limited in 17
patients. Reactivation of CMV and EBV occurred in 41 (29.5%) and 41 (29.5%) patients, respectively.
Twenty patients (14.4%) met criteria for invasive aspergillosis. TRM at 6 and 12 months after allo-SCT was 8.7 and 11.1%, respectively. The median PFS and OS for all patients, as well as for the subgroups of patients who received allo-SCT as part of first line treatment or in the relapse setting, is shown in Table 2 .
Secondary MGUS
Sixty-seven (48.2%) of the patients developed at least one sMGUS after allo-SCT. A total of 217 new bands were identified. Twenty-five patients had only one new protein band (18.0%), 9 (6.5%) had 2 bands, 8 (5.8%) had 3 bands, and 25 (18.0%) had four or more. The most common types of secondary MGUS were IgG-kappa (31.3%), IgG lambda (25.3%), IgM lambda (10.6%), and IgM kappa (7.8%). In most cases it was not possible to quantify the level of sMGUS. Abnormal protein bands could be quantified in only 4 patients, with a maximum level of 11 g/L.
Secondary MGUS first appeared after a median latency of 6.9 months (range 1. Other factors associated with both PFS and OS after allo-SCT are age at the time of allo-SCT, extent of prior treatment, chronic GvHD, use of novel agents, stem cell source, T-cell depletion, and remission status after allo-SCT. In addition, development of acute GvHD and a non-myeloablative conditioning regimen predicted for improved PFS, and presence of HLA mismatch for inferior OS (Table 3) .
Multivariate Cox regression analysis
Multivariate Cox regression analysis showed that development of sMGUS as a time-dependent 
Discussion
This is the first study that evaluates the significance of sMGUS in MM patients treated with allo-SCT.
In our population, almost half of the MM and pPCL patients developed sMGUS after allo-SCT, which was associated with an improved outcome. In at least 27.6% of the patients, the isotype did not differ from the original M-protein, but had a different migration pattern. The high frequency of post-transplant MGUS clearly demonstrates the importance for clinicians to recognize this benign phenomenon, so that it will not be confused with relapse or progression of disease.
Importantly, development of sMGUS after allo-SCT was associated with a better quality of response, as well as significantly improved PFS and OS, both in patients transplanted in the upfront setting and at the time of relapse. Since development of sMGUS is a post-allo-SCT event, we included sMGUS as a time-dependent variable in both univariate and multivariate Cox regression analysis, and
we complemented these studies with a landmark analysis. The association of development of sMGUS with an improved outcome after allo-SCT as demonstrated in this study, is consistent with several other reports that showed a better survival in MM patients with emergence of sMGUS after autologous SCT or chemotherapy 1;2;4;6;9;10;12-14;17 . However, some studies did not observe a favorable outcome in patients with sMGUS. This may be related to differences in sample size, duration of follow-up, technical and procedural variability, use of novel agents, and the percentage of patients that underwent autologous transplantation, or as shown here, allo-SCT. Importantly, we show that emergence of sMGUS is an independent predictor of PFS and OS after allo-SCT, with improved PFS and OS also in those patients achieving CR or VGPR after allo-SCT.
The oligoclonal bands appeared after a median of 6.9 months after allo-SCT. The emergence of sMGUS reflects a strong humoral immune response and is a sign of immune reconstitution after allo-SCT, autologous SCT, or novel agent-containing regimens. We and others observed a higher frequency of sMGUS in patients with high-quality responses, which suggests that major tumor reduction contributes to strong immune reconstitution and development of oligoclonal bands. Furthermore, one study demonstrated that patients receiving myeloablative conditioning prior to allo-SCT had a higher incidence of post-transplant MGUS 19 . In our series conditioning had no effect on the incidence of post-transplant MGUS, which may be explained by the infrequent use of myeloablative conditioning regimens in our patients. In contrast to other studies 7;16;17 , we observed a lower incidence of sMGUS in patients who received novel agent-based induction therapy, which is probably explained by the less frequent use of novel agents in patients who received allo-SCT as part of first line treatment, compared to patients who were transplanted in the relapse setting. Interestingly, lenalidomide was used more frequently than bortezomib in patients with relapsed disease. This preference for lenalidomide may be related to the presence of polyneuropathy due to prior bortezomib and thalidomide therapy, and its convenience of oral administration. Lenalidomide was not part of first- There is no evidence that these abnormal protein bands are related to the myeloma clone.
Guikema et al used ASO-PCR and DNA sequencing to demonstrate that new serum M-components after auto-SCT are not produced by myeloma cells but rather by the regenerating B-cell compartment 31 . Furthermore, sMGUS not only occurs in MM patients but also after treatment for other hematologic malignancies and even solid organ transplantations 19;20;23;25 .
It is currently not clear which antigens trigger the oligoclonal humoral immune response leading to sMGUS. Some studies found associations between occurrence of sMGUS and CMV or EBV reactivation or development of (acute/chronic) GvHD 19;23; [32] [33] [34] [35] . This suggests that oligoclonal bands may represent the generation of an immune response to infectious agents or that the oligoclonal bands mediate alloimmune reactions after allo-SCT. In our study we demonstrated a trend towards a higher incidence of post-transplant MGUS in the presence of chronic GvHD, but no association with CMV, EBV, or aspergillus infections. In addition, the favorable prognosis conferred by sMGUS suggests that the oligoclonal bands may also be involved in an anti-myeloma immune response. Interestingly, a recent study showed that oligoclonal bands also target recurrent myeloma antigens, including MAGEA4 and heat-shock proteins 36 .
Limitations to this study are in a great part related to the retrospective design. There were no fixed moments of follow-up. In addition, the patients received different induction and conditioning regimens prior to allo-SCT, and also treatment of relapse after transplantation was heterogeneous among the patients. Furthermore, this study encompassed a 12-year time period, during which treatment and supportive care rapidly evolved.
We conclude that development of sMGUS after allo-SCT is a favorable prognostic factor for PFS and OS, independent of the response achieved after allo-SCT. Importantly, clinicians should be aware that sMGUS does not represent disease recurrence or development of a new malignancy to avoid unnecessary treatment.
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